Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: HIV -1 Infection
Interventions: GS-0415, GS-0415 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami Lakes, Florida + 12 more

Conditions: Hemorrhagic Stroke, Ischemic Stroke
Interventions: SENSE Device; Device
Lead sponsor: Sense Diagnostics, LLC; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805, FOLFIRI regimen; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Hypercholesterolemia
Interventions: CIVI 007; Drug
Lead sponsor: Civi Biopharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Port Orange, Florida • Indianapolis, Indiana + 4 more

Conditions: Multiple Sclerosis
Interventions: Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 99
States / cities: Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more

Conditions: Asthma in Children
Interventions: Prednisolone; Drug
Lead sponsor: University of Florida; Other
Eligibility: 2 Years to 18 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: DeFuniak Springs, Florida • Fort Myers, Florida • Sarasota, Florida + 4 more

Conditions: Mitral Valve Regurgitation
Interventions: MitraClip™ device implantation, Mitral Valve Repair Surgery; Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 63
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 47 more

Conditions: Migraine
Interventions: Placebo ZNS, ZNS; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more

Conditions: Healthy Adults
Interventions: Norovirus; Biological
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 49 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatitis C Virus
Interventions: Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: Advanced Renal Cell Carcinoma (RCC)
Interventions: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 17
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, sitagliptin, metformin, sulphonylurea; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more

Conditions: Myelofibrosis
Interventions: Placebo, Ruxolitinib, Vismodegib; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 3 more

Conditions: Congenital Heart Disease
Interventions: Treprostinil, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Osteoarthritis
Interventions: Meloxicam Test Capsules, Placebo Capsules; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Carmichael, California • Pismo Beach, California + 31 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Sleep Intervention, Melatonin; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 12 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
Interventions: ZD1839 (Gefitinib); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 626
States / cities: Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more

Conditions: Rosacea
Interventions: IDP-115, Vehicle; Drug
Lead sponsor: Dow Pharmaceutical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Huntsville, Alabama • San Diego, California • Vallejo, California + 7 more

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee

Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Vorinostat; Radiation · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 37 Months to 21 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 174
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 129 more

Conditions: Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic, Hypoxic-Ischemic Encephalopathy, Ischemic-Hypoxic Encephalopathy
Interventions: Hypothermia, Normothermic Control; Device · Procedure
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 33 Weeks to 35 Weeks
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 14 more

Conditions: Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Hepatic Cancer, Hepatic Carcinoma
Interventions: H3B-6527; Drug
Lead sponsor: H3 Biomedicine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Los Angeles, California • Newport Beach, California • Orange, California + 11 more

Conditions: Multiple Myeloma
Interventions: P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate; Biological · Drug
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2042
U.S. locations: 23
States / cities: Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more

Conditions: Colorectal Cancer
Interventions: Blood Sample Collection; Other
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 40 Years and older
Enrollment: 23,494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 194
States / cities: Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 160 more

Search by objective public record fields.

Study of GS-0415 and How It Works in People With HIV

Early Feasibility Study of the SENSE Device

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Early Administration of Steroids in the Ambulance Setting

MitraClip REPAIR MR Study

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

Acute Effects of Inhaled Treprostinil in Fontan Patients

Study of Meloxicam Capsules to Treat Osteoarthritis Pain

Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)

Iressa Expanded Access Program (EAP)

A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Preemie Hypothermia for Neonatal Encephalopathy

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"